Willeke Peter, Schlüter Bernhard, Limani Armend, Becker Heidemarie, Schotte Heiko
Section of Rheumatology and Clinical Immunology/Department of Medicine D, University Hospital Münster, Albert Schweitzer Campus A1, 48149, Muenster, Germany.
Centre for Laboratory Medicine, University Hospital Münster, Muenster, Germany.
Clin Rheumatol. 2016 Feb;35(2):387-94. doi: 10.1007/s10067-015-2882-5. Epub 2015 Jan 30.
The aim of the study was to investigate the incidence, the clinical course and outcome of liver involvement and autoimmune hepatic diseases in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Liver function tests (LFT) (i.e. aspartate and alanine aminotransferase [AST, ALT], gamma-glutamyl transpeptidase [gamma-GT], alkaline phosphatase [ALP] and total bilirubin) were analysed at disease onset in therapy-naïve patients and during remission in patients with granulomatosis with polyangiitis (GPA, n = 67), microscopic polyangiitis (MPA, n = 28) and eosinophilic granulomatosis with polyangiitis (EGPA, n = 14). Results were correlated to the Birmingham Vasculitis Activity Score version 3 (BVAS v.3). Also, serologic tests for other autoimmune hepatic diseases were performed in these patients. During the active state, LFT abnormalities could be detected in 54 AAV patients (49.4 %). ALT, gamma-GT and ALP were significantly higher in GPA patients compared to MPA or EGPA patients at disease onset (p < 0.05). Increased values for gamma-GT in GPA patients correlated with the BVAS (p < 0.01) and were associated with pulmonary involvement, pulmonary-renal syndrome and a longer time to remission. Increased LFT in GPA patients decreased subsequently towards normal levels after initiation of therapy (p < 0.01). No case of severe liver involvement or autoimmune hepatic liver diseases was found in AAV patients. Liver involvement was mainly restricted to GPA patients, is associated with the disease activity and indicates a poorer outcome in patients with GPA. Progressive liver involvement or autoimmune hepatic diseases were not observed.
本研究旨在调查抗中性粒细胞胞浆抗体(ANCA)相关血管炎(AAV)患者肝脏受累及自身免疫性肝病的发病率、临床病程和结局。对初治患者疾病发作时以及肉芽肿性多血管炎(GPA,n = 67)、显微镜下多血管炎(MPA,n = 28)和嗜酸性肉芽肿性多血管炎(EGPA,n = 14)患者缓解期的肝功能检查(LFT)(即天冬氨酸和丙氨酸转氨酶[AST、ALT]、γ-谷氨酰转肽酶[γ-GT]、碱性磷酸酶[ALP]和总胆红素)进行分析。结果与伯明翰血管炎活动评分第3版(BVAS v.3)相关。此外,还对这些患者进行了其他自身免疫性肝病的血清学检查。在活动期,54例AAV患者(49.4%)可检测到LFT异常。疾病发作时,GPA患者的ALT、γ-GT和ALP显著高于MPA或EGPA患者(p < 0.05)。GPA患者γ-GT值升高与BVAS相关(p < 0.01),并与肺部受累、肺肾综合征及缓解时间延长有关。GPA患者开始治疗后,升高的LFT随后降至正常水平(p < 0.01)。AAV患者未发现严重肝脏受累或自身免疫性肝病病例。肝脏受累主要局限于GPA患者,与疾病活动相关,提示GPA患者预后较差。未观察到进行性肝脏受累或自身免疫性肝病。